1. Reversal Strategies for VKA: Truths and Misconceptions

3. Program Objectives

4. Typical Indications for Anticoagulation Therapy

5. The Coagulation Cascade: Pathways and Factors

6. Coagulation Cascade and Activity Sites of Anticoagulant Therapeutics

7. Warfarin MoA[a,b]

8. Pharmacologic Properties of Selected Oral Anticoagulants

9. Reasons for Urgent Anticoagulation Reversal

10. Reversal Agents for VKA-Associated Anticoagulation

11. VKA Therapy Reversal With Vitamin K

12. FFP for Anticoagulation Reversal

13. Management of Urgent Anticoagulation Reversal

14. Volume Overload and Anticoagulation Reversal With FFP

15. RE-LY Study: Risk of Major Bleeding (% of Patients)

16. Efficacy and Safety of a 4F-PCC in Patients on VKAs Presenting With Major Bleeding: Key Results From a Phase 3b Study

17. Outcomes of Urgent Warfarin Reversal With FFP vs 4F-PCC

18. 4F-PCC vs Plasma for Rapid VKA Reversal in Patients Needing Urgent Surgical or Invasive Interventions: Primary Endpoint Results

19. 4F-PCC vs Plasma for Rapid VKA Reversal in Patients Needing Urgent Surgical or Invasive Interventions: Adverse Events

20. Increased Risk of Volume Overload With Plasma Compared With 4F-PCC

21. Thromboembolic Events Over Time: Plasma vs 4F-PCC

22. Recombinant FVIIa vs 3F-PCC

23. Warfarin Reversal by 4F-PCC

24. Relative Efficacy of Strategies for Reversal of Oral Anticoagulation

25. Therapeutic Interventions for Reversal of Oral Anticoagulants Based on Urgency[a-e]

26. What Do Guidelines Recommend?

27. Updated European Heart Rhythm Association Practical Guide: Management of NOAC-Associated Bleeding

28. Conclusions

29. Abbreviations

30. Abbreviations (cont)